340B audit imbalances under fire at Senate panel

The 340B Drug Pricing Program took center stage at the Senate's HELP panel for the third time in several months on Tuesday, this time turning the focus to audits of hospitals and drug manufacturers conducted by the Health Resources and Services Administration​. HRSA Director Krista Pedley said that in the past five years, 12 of 600 program manufacturers faced audits compared to 981 of 12,700 of hospitals, also known as covered entities.